Phesgo Pertuzumab and Trastuzumab Injection

1. Indications and Usage
Early Breast Cancer (EBC):
Indicated for the treatment of adult patients with HER2-positive early breast cancer.
Neoadjuvant Setting: In combination with chemotherapy for patients with tumors >2 cm or node-positive disease.
Adjuvant Setting: For patients with high-risk HER2-positive early breast cancer.
Metastatic Breast Cancer (MBC):
Indicated for adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, to be used in combination with docetaxel.
2. Dosage and Administration
Route of Administration:
For Subcutaneous Injection (SC) ONLY. Do not administer intravenously (IV).
Recommended Dosage:
Loading Dose: Pertuzumab 1200 mg + Trastuzumab 600 mg administered once every 3 weeks.
Maintenance Dose: Pertuzumab 600 mg + Trastuzumab 600 mg administered once every 3 weeks.
Administration Instructions:
Administer as a subcutaneous injection into the thigh over approximately 5 to 8 minutes.
Inject into alternating thighs for subsequent doses.
Do not administer into areas where the skin is reddened, bruised, tender, or indurated.
Missed Dose:
If the time between doses is <6 weeks, administer the maintenance dose as soon as possible.
If the time between doses is ≥6 weeks, re-administer the loading dose.
3. Mechanism of Action
Dual HER2 Blockade:
Pertuzumab and Trastuzumab are both recombinant humanized IgG1 monoclonal antibodies that bind to the extracellular domain of the HER2 receptor, but at different epitopes (Domain II and Domain IV, respectively).
Synergistic Inhibition:
Trastuzumab: Primarily inhibits downstream signaling (PI3K/Akt) and mediates antibody-dependent cellular cytotoxicity (ADCC).
Pertuzumab: Primarily inhibits HER2 dimerization (specifically HER2-HER3 heterodimerization).
The combination results in more complete blockade of HER2 signaling pathways and enhanced immune-mediated tumor cell killing compared to either antibody alone.
4. Safety and Warnings
Cardiotoxicity (Left Ventricular Dysfunction):
Can cause a decrease in left ventricular ejection fraction (LVEF). Monitor LVEF prior to initiation and at regular intervals during treatment. Discontinue if significant LVEF decline occurs.
Embryo-Fetal Toxicity:
Can cause fetal harm. Pregnancy testing is recommended before initiating treatment. Females of reproductive potential must use effective contraception during treatment and for at least 7 months after the final dose.
Infusion-Related Reactions:
Hypersensitivity reactions can occur. Monitor patients during administration.
5. Adverse Reactions
Most Common:
Nausea, diarrhea, rash, fatigue, vomiting, neutropenia, leukopenia, and anemia.
Specific to Subcutaneous Formulation:
Injection site reactions (e.g., erythema, swelling) are common.
6. Drug Interactions
Anthracyclines:
Concomitant use with anthracyclines (e.g., doxorubicin, epirubicin) is generally not recommended due to the increased risk of cardiotoxicity, particularly in the adjuvant setting.
Carcinogenicity:
Long-term animal studies have not been performed to evaluate the carcinogenic or mutagenic potential of the combination.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredients: Pertuzumab and Trastuzumab.
Formulation: Fixed-dose combination solution for injection.
Appearance: Clear to slightly opalescent, colorless to light brownish-yellow liquid.
Storage: Store in the original package at 2°C to 8°C (36°F to 46°F). Do not freeze or shake vigorously.